Dartmouth-Hitchcock Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Dartmouth-Hitchcock Medical Center sits in the top decile of US sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count).

427 total trials 52 currently recruiting 300 completed early-phase tilt top decile by trial count

Dartmouth-Hitchcock Medical Center: 427 sponsored US clinical trials, 52 recruiting.

Dartmouth-Hitchcock Medical Center sponsors 427 registered US clinical trials on ClinicalTrials.gov, 52 of them currently recruiting, and 300 completed. 25 of these trials are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.

Top-decile sponsor footprint

Dartmouth-Hitchcock Medical Center ranks in the top decile of sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 53/100

300 of 352 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

427 total, page 7 of 9

COMPLETED NA

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

NCT01391559

COMPLETED NA

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

NCT01755455

COMPLETED Phase 4

Effect of Ketoconazole on Breathlessness

NCT01378520

COMPLETED NA

Electronic Decision Support Systems for Smokers With Severe Mental Illness

NCT01412866

TERMINATED

Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

NCT01466504

COMPLETED Phase 3

Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders

NCT01457404

COMPLETED Phase 3

Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment

NCT01457391

COMPLETED NA

Helping Patients With Spinal Stenosis Make a Treatment Decision: A Randomized Study Assessing The Benefits of Health Coaching

NCT01263678

COMPLETED NA

Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)

NCT01245621

COMPLETED NA

Participation Restrictions in Breast Cancer Survivors

NCT01225328

COMPLETED Phase 2

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

NCT01234766

COMPLETED Phase 2

Phase II Study of Alternating Sunitinib and Temsirolimus

NCT01517243

COMPLETED

Establishing Standards for Normal Pancreatic EUS

NCT02868047

COMPLETED Phase 2

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

NCT01165541

TERMINATED

Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research

NCT01382615

TERMINATED

NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo

NCT01934114

COMPLETED

Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer

NCT01510405

COMPLETED Phase 2

Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer

NCT01653327

TERMINATED Phase 2

Metronomic Therapy in Patients With Metastatic Melanoma

NCT01542255

COMPLETED

Immune Status in Solid Organ Transplantation

NCT01070901

COMPLETED

The Neuroeconomics of Behavioral Therapies for Adolescent Substance Abuse

NCT01093898

COMPLETED Early Phase 1

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

NCT01091792

TERMINATED Phase 1

A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors

NCT00951158

TERMINATED NA

Phyllodes Tumor Partial Breast Radiation Study

NCT01089374

COMPLETED NA

Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction

NCT01038713

COMPLETED Phase 1

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

NCT00946348

TERMINATED Early Phase 1

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

NCT01015300

COMPLETED Phase 1

Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI)

NCT00817154

COMPLETED NA

Microelectrodes in Epilepsy

NCT05200455

COMPLETED NA

Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI

NCT02334280

COMPLETED NA

A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery

NCT01929395

COMPLETED NA

Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)

NCT00958919

COMPLETED Early Phase 1

Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue

NCT00908791

COMPLETED

Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas

NCT00942760

COMPLETED

Protocol to Obtain Blood Samples for Leukemia Research

NCT00889031

COMPLETED NA

A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer

NCT00735826

TERMINATED NA

Harmonic Scalpel Vs. Electrocautery in Breast Reduction Surgery

NCT00819260

COMPLETED

Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging

NCT01060085

TERMINATED Phase 2

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

NCT00913913

COMPLETED NA

Randomized ActiveStep Clinical Evaluation

NCT00810082

COMPLETED NA

Development and Efficacy Test of Computerized Treatment for Marijuana Dependence

NCT00594659

COMPLETED Phase 4

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

NCT00754546

COMPLETED NA

Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses

NCT00494650

TERMINATED Phase 2

Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

NCT00665652

COMPLETED

Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation

NCT00889278

COMPLETED

Evaluation of Body-worn Multimodal Hand Hygiene System. Impact on Health-Care Associated Infections

NCT01050608

COMPLETED NA

Treatment for Adolescent Marijuana Abuse

NCT00580671

COMPLETED NA

Minimally Invasive Knee Replacement Outcomes (MIKRO) Study

NCT00633113

COMPLETED Phase 4

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

NCT01460225

COMPLETED NA

Family Based Contingency Management for Adolescent Alcohol Abuse

NCT00595478

← Previous Page 7 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 44
Phase 2 40
Phase 3 6
Phase 4 19

What is open in the Dartmouth-Hitchcock Medical Center pipeline

52 recruiting of 427 indexed (12% open); 300 completed (70%).

Phase mix: 25 late (III/IV) vs 84 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Dartmouth-Hitchcock Medical Center: open-pipeline peers nationwide

Peers matched on 427 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%10%20%30% Total trials Recruiting share Dartmouth-Hitchcock Medical CenterUniversity of Illinois at ChicagoVanderbilt UniversityChildren's Hospital of PhiladelphiaNovo Nordisk A/SFriends Research InstituteAntonios LikourezosOregon State UniversityUniversity of Massachusetts, Amherst
Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 427 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this Dartmouth-Hitchcock Medical Center page

427 registered trials is a research-attention snapshot, not an endorsement of Dartmouth-Hitchcock Medical Center or any single study.

  • 52 of Dartmouth-Hitchcock Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Dartmouth-Hitchcock Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dartmouth-Hitchcock Medical Center pipeline card: 427 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.